Team Introductions: Memorial Sloan Kettering “Yankees” vs Dana-Farber “Red Sox”

News
Video

Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

Ashley Chan
June 18th 2025
Article

Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Chris Ryan
June 17th 2025
Article

Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.